Aisling Capital Management LP
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 8, 2024), Aisling Capital Management LP reported 15 stock positions worth $231.1 million. Its top holding was Bridgebio Pharma (BBIO) at 66.5% of the portfolio, followed by Syndax Pharmaceuticals (SNDX, 9.1%) and Verona Pharma (VRNA, 7.0%). Compared with Q1 2024, it opened 1 new position and sold out of 2. The biggest buy was a new position in Tectonic Therapeutic (TECX) and the biggest sale an exit from Avrobio.
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001766721
- Portfolio Value
- $231.1M (Q2 2024)
- SEC Filing
- 0001766721-24-000004 ↗ filed Aug 8, 2024
Holdings Value
Holdings 15 stocks · $231.1M
| BBIO Bridgebio Pharma Inc. | 66.52% | 6,068,125 | $153.7M | No change |
| SNDX Syndax Pharmaceuticals Inc. | 9.11% | 1,025,000 | $21.0M | No change |
| VRNA Verona Pharma Ltd. | 6.98% | 1,115,352 | $16.1M | No change |
| ELEV Elevation Oncology Inc. | 3.31% | 2,834,910 | $7.7M | No change |
| NUVB Nuvation Bio Inc. | 3.21% | 2,541,009 | $7.4M | No change |
| CMPS Compass Pathways PLC | 2.52% | 964,500 | $5.8M | No change |
| GLUE Monte Rosa Therapeutics Inc. | 2.38% | 1,472,331 | $5.5M | No change |
| BMEA Biomea Fusion Inc. | 1.56% | 798,757 | $3.6M | No change |
| PSTX Poseida Therapeutics Inc. | 1.32% | 1,043,267 | $3.0M | No change |
| CALC Calcimedica Inc. | 0.89% | 521,114 | $2.1M | No change |
| MRKR Marker Therapeutics Inc. | 0.74% | 314,286 | $1.7M | No change |
| TECX Tectonic Therapeutic Inc. | 0.60% | 84,148 | $1.4M | New |
| RENEO PHARMACEUTICALS INC | 0.58% | 886,075 | $1.3M | No change |
| ACRS Aclaris Therapeutics Inc. | 0.21% | 434,455 | $478K | No change |
| VIRX Viracta Therapeutics Inc. | 0.07% | 288,571 | $157K | No change |
Portfolio Sells Q1 2024 → Q2 2024
| AVROBIO INC | Sold out | 0.00% | −0.44 |
| SPRB Spruce Biosciences Inc. | Sold out | 0.00% | −0.32 |
Portfolio Buys Q1 2024 → Q2 2024
| TECX Tectonic Therapeutic Inc. | New | 0.60% | +0.60 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 14 | $471.6M | BBIO, GLUE, SNDX, CMPS, BCAX |
| Q1 2026 | 13 | $476.3M | BBIO, SNDX, GLUE, BCAX, BBOT |
| Q4 2025 | 13 | $478.9M | BBIO, SNDX, GLUE, BCAX, CMPS |
| Q3 2025 | 14 | $456.4M | BBIO, VRNA, SNDX, NUVB, GLUE |
| Q2 2025 | 13 | $359.7M | BBIO, VRNA, SNDX, GLUE, BCAX |
| Q1 2025 | 13 | $288.5M | BBIO, VRNA, SNDX, BCAX, GLUE |
| Q4 2024 | 15 | $281.8M | BBIO, VRNA, SNDX, GLUE, PSTX |
| Q3 2024 | 16 | $261.1M | BBIO, VRNA, SNDX, BCAX, BMEA |
| Q2 2024 | 15 | $231.1M | BBIO, SNDX, VRNA, ELEV, NUVB |
| Q1 2024 | 16 | $295.5M | BBIO, SNDX, VRNA, ELEV, BMEA |